Bionano Genomics Dividend

Dividend criteria checks 0/6

Bionano Genomics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	0.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.48
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

May 09

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Mar 14

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Oct 18

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Sep 23

Bionano jumps 36% as publication highlights optical genome mapping

Aug 11

Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss

Aug 04

Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities

Jun 29

I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics

Jun 23

Here's Why We're Not Too Worried About Bionano Genomics' (NASDAQ:BNGO) Cash Burn Situation

Apr 11

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BNGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNGO's dividend payments have been increasing.

Dividend Yield vs Market

Bionano Genomics Dividend Yield vs Market

How does BNGO dividend yield compare to the market?
Segment	Dividend Yield
Company (BNGO)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Life Sciences)	0.4%
Analyst forecast in 3 Years (BNGO)	n/a

Notable Dividend: Unable to evaluate BNGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BNGO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNGO has not reported any payouts.

Bionano Genomics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Shareholder dilution

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$6.81 loss per share (vs US$4.59 loss in FY 2022)

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Consensus EPS estimates fall by 20%

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Price target increased by 10% to US$12.33

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

New minor risk - Market cap size

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Price target decreased by 17% to US$35.40

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Price target decreased by 14% to US$3.68

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Full year 2022 earnings: EPS misses analyst expectations

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$7.38

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Independent Director exercised options and sold US$65k worth of stock

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Bionano jumps 36% as publication highlights optical genome mapping

Consensus forecasts updated

Bionano Genomics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss

Bionano Genomics, Inc. Announces Publication of Research Study in Myelodysplastic Syndrome

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Chromosome Instability During Culture of Induced Pluripotent Stem Cells

Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities

I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders

Bionano Genomics, Inc. Reports First Published Study of OGM in Pediatric AML Shows OGM Identifies MRD Markers and Other Novel Variants That Can Impact Case Management

Independent Chairman of the Board recently bought US$16k worth of stock

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$8.75

High number of new directors